Literature DB >> 1084886

Comparison of the chemical, physical, and survival properties of normal and Z-variant alpha-1-antitrypsins.

R R Miller, M S Kuhlenschmidt, C J Coffee, I Kuo, R H Glew.   

Abstract

A procedure has been developed for the purification of Z-type alpha-1-antitrypsin (alpha-1-AT) which is rapid, gentle, and results in good yields. From 4 units (750 ml) of fresh human plasma, obtained from two individuals possessing the Pizz phenotype, 53 mg of pure Z-type alpha-1-AT was obtained. The preparation was homogeneous by the criteria of polyacrylamide gel electrophoresis, both in the presence and absence of sodium dodecyl sulfate, and by analytical ultracentrifugation. When compared to pure alpha-1-AT from plasma of individuals possessing the normal PiMM phenotype, the two proteins were indistinguishable with respect to amino acid composition, sedimentation coefficient (s20w of 3.33 for both M and Z), molecular weight (51,000 by sodium dodecyl sulfate gel electrophoresis and 47,000 by sedimentation equilibrium for both M and Z), and trypsin-combining ratio (0.91 for Z and 0.99 for M). The only difference which was observed between the variant forms of alpha-1-AT was in the carbohydrate composition. The Z-type alpha1-AT contains between 20 and 25% less carbohydrate than the M-type alpha-1-AT. Specifically, the Z-type alpha-1-AT is deficient in 1 glucosamine residue, 3 neutral sugar residues (1 mannose and 2 galactose), and 2 sialic acid residues. Although the Z-variant is deficient in sialic acid, its survival time in the serum of a rabbit was not significantly different from that of M-type alpha-1-AT.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1084886

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342.

Authors:  A A McCracken; K B Kruse; J L Brown
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

2.  Isolation and characterization of alpha 1-antitrypsin in PAS-positive hepatic granules from rats with experimental alpha 1-antitrypsin deficiency.

Authors:  S Bolmer; J Kleinerman
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

3.  Isolation and partial characterization of rabbit plasma alpha1-antitrypsin.

Authors:  A Koj; M W Hatton; K L Wong; E Regoeczi
Journal:  Biochem J       Date:  1978-03-01       Impact factor: 3.857

4.  High-level production of biologically active human alpha 1-antitrypsin in Escherichia coli.

Authors:  M Courtney; A Buchwalder; L H Tessier; M Jaye; A Benavente; A Balland; V Kohli; R Lathe; P Tolstoshev; J P Lecocq
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

5.  [Alpha 1-antitrypsin deficiency: a review with special reference to the significance of heterozygous deficiency].

Authors:  M Schneider; G Pott; U Gerlach
Journal:  Klin Wochenschr       Date:  1986-03-03

Review 6.  Human gene therapy: present and future.

Authors:  M A Kay; K P Ponder; S L Woo
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Influence of acute-phase proteins on the activity of natural killer cells.

Authors:  Y Okumura; J Kudo; T Ikuta; S Kurokawa; H Ishibashi; H Okubo
Journal:  Inflammation       Date:  1985-06       Impact factor: 4.092

8.  Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase.

Authors:  F Ogushi; G A Fells; R C Hubbard; S D Straus; R G Crystal
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

9.  Galactosamine-induced alpha 1-antitrypsin deficiency in rats. Alterations in plasma glycoproteins and alpha 1-antitrypsin carbohydrate composition.

Authors:  S D Bolmer; J Kleinerman
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

10.  Synthesis of abnormal immunoglobulins by hybridomas from autoimmune "viable motheaten" mutant mice.

Authors:  P A Schweitzer; S E Taylor; L D Shultz
Journal:  J Cell Biol       Date:  1991-07       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.